8 April 2014Americas

Teva asks US Supreme Court to stay ruling in Copaxone case

Teva has filed an application with the US Supreme Court to stay a ruling by the US Court of Appeals for the Federal Circuit that allowed generic drug makers to enter the market before the expiry of Teva’s patents covering its $4.3 billion-a-year multiple sclerosis drug Copaxone (glatiramer acetate).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics file Teva response in Copaxone battle

15 April 2014 A group of generic drug manufacturers has asked the US Supreme Court to allow a ruling that grants them permission to market a version of Teva’s multiple sclerosis drug Copaxone (glatiramer acetate).

US Supreme Court split on Teva case

16 October 2014 The US Supreme Court was split yesterday (October 15) after hearing arguments in a high-profile case that will determine whether generic drug companies are free to market a cheaper version of Teva’s blockbuster multiple sclerosis drug.

More on this story

Generics file Teva response in Copaxone battle

15 April 2014 A group of generic drug manufacturers has asked the US Supreme Court to allow a ruling that grants them permission to market a version of Teva’s multiple sclerosis drug Copaxone (glatiramer acetate).

US Supreme Court split on Teva case

16 October 2014 The US Supreme Court was split yesterday (October 15) after hearing arguments in a high-profile case that will determine whether generic drug companies are free to market a cheaper version of Teva’s blockbuster multiple sclerosis drug.

More on this story

Generics file Teva response in Copaxone battle

15 April 2014 A group of generic drug manufacturers has asked the US Supreme Court to allow a ruling that grants them permission to market a version of Teva’s multiple sclerosis drug Copaxone (glatiramer acetate).

US Supreme Court split on Teva case

16 October 2014 The US Supreme Court was split yesterday (October 15) after hearing arguments in a high-profile case that will determine whether generic drug companies are free to market a cheaper version of Teva’s blockbuster multiple sclerosis drug.

More features

Gene tech firm fends off injunction in test kit dispute

Comparing life sciences IP in Brazil and the US

Gilead awarded $30m over counterfeit HIV drug scheme

EPO invalidates human milk patent after Nestle opposition

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal